世界のバイオ医薬品市場の規模、シェア、トレンド分析レポート – 業界の概要と2031年までの予測

Get Exclusive Sample PDF of this Report Here

バイオ医薬品市場分析

バイオ医薬品市場は、革新的な治療法の需要の高まりとバイオテクノロジーの進歩により、大幅な成長を遂げています。生物由来のバイオ医薬品には、モノクローナル抗体、ワクチン、組み換えタンパク質など、がん、自己免疫疾患、感染症などのさまざまな疾患の治療に役立つ幅広い製品が含まれます。慢性疾患の増加と個別化医療の必要性が、市場の拡大をさらに推進しています。高度な遺伝子治療の導入や医薬品開発プロセスへの人工知能の統合などの最近の開発により、バイオ医薬品の効率と有効性が向上しました。さらに、支援的な規制枠組みと研究開発への投資の増加により、この分野でのイノベーションが促進されると期待されています。その結果、バイオ医薬品市場は継続的な成長が見込まれ、新しい治療オプションが提供され、世界中で患者の転帰が改善されます。

バイオ医薬品市場規模

世界のバイオ医薬品市場規模は、2023年に10億2,000万米ドルと評価され、2024年から2031年の予測期間中に6%のCAGRで成長し、2031年までに26億2,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

バイオ医薬品市場の動向

「標的治療の需要が高まる」

バイオ医薬品市場は、技術の進歩と標的療法の需要の高まりに牽引され、急速に進化しています。個別化医療や生物製剤を含む医薬品開発プロセスの革新は、さまざまな疾患の治療環境を一変させています。注目すべき傾向の 1 つは、がんや自己免疫疾患などの治療に有効性が示されているモノクローナル抗体の使用増加です。これらの人工タンパク質は、疾患経路を正確に標的とするため、有効性が向上し、副作用が減少します。さらに、バイオシミラーの台頭により、市場での競争とアクセス性が高まり、費用対効果の高い治療オプションが可能になります。全体として、これらの傾向は、バイオ医薬品セクターの継続的な変革を浮き彫りにし、より効果的でカスタマイズされた治療ソリューションへの道を開いています。

レポートの範囲とバイオ医薬品市場のセグメンテーション

Get Exclusive Sample PDF of this Report Here

バイオ医薬品市場の定義

バイオ医薬品は、生きた細胞や生物などの生物学的資源を利用してバイオテクノロジーを使用して生産される医薬品です。化学的に合成されることの多い従来の医薬品とは異なり、バイオ医薬品は、タンパク質、核酸、炭水化物などの大きく複雑な分子であることが一般的です。バイオ医薬品は特定の疾患や症状をターゲットに設計されており、より効果的で個別の治療オプションを提供することがよくあります。たとえば、バイオ医薬品には、がん、糖尿病、自己免疫疾患などのさまざまな疾患の治療に使用されるモノクローナル抗体、ワクチン、組み換えタンパク質が含まれます。バイオ医薬品の開発には、遺伝子工学や組み換え DNA 技術などの高度な技術が関与しており、現代医学の治療環境に革命をもたらした革新的な治療法につながっています。

バイオ医薬品市場の動向

ドライバー

• 慢性疾患の増加

がん、糖尿病、自己免疫疾患などの慢性疾患の罹患率の増加により、効果的な治療オプションの需要が大幅に高まり、バイオ医薬品市場の成長を牽引しています。これらの疾患が広まるにつれて、患者は従来の治療法よりも優れた有効性と安全性プロファイルを備えた革新的な治療法を求めています。モノクローナル抗体や標的療法などのバイオ医薬品は、特定の生物学的経路を標的とすることで、これらの慢性疾患の複雑さに対処するように特別に設計されています。このカスタマイズされたアプローチにより、患者の転帰が改善され、罹患した人々の生活の質が向上します。さらに、バイオテクノロジーの継続的な進歩により、これらの慢性疾患に効果的なソリューションを提供できる新しいバイオ医薬品の継続的な開発が可能になり、現代のヘルスケアにおけるバイオ医薬品の重要性が強化され、市場全体の成長に貢献しています。

• 認知度と採用の拡大

The growing awareness among healthcare professionals and patients regarding the benefits of biopharmaceutical therapies significantly contributes to their acceptance and utilization in clinical settings. As education and information dissemination improve, medical practitioners are increasingly recognizing the efficacy and potential of biopharmaceuticals in treating various diseases, particularly chronic and complex conditions. Patients, informed by healthcare providers and advocacy groups, are also more willing to explore these advanced therapeutic options, leading to increased demand. This heightened understanding encourages healthcare systems to integrate biopharmaceutical therapies into treatment protocols, further driving market growth.

Opportunities

• Expansion of Biosimilars

The growing acceptance and regulatory approval of biosimilars represent a substantial opportunity for biopharmaceutical market players to provide cost-effective alternatives to existing branded medications. Biosimilars, which are highly similar to already approved biologic products, offer comparable efficacy and safety profiles, allowing healthcare providers to choose more affordable treatment options for patients. This is particularly significant in the context of rising healthcare costs and the need for accessible treatments, especially for chronic conditions such as cancer and autoimmune diseases. As healthcare systems worldwide strive to manage expenses while maintaining high-quality care, the demand for biosimilars is expected to increase. Consequently, companies that invest in the development and marketing of biosimilars can enhance patient access to essential medications while capitalizing on this lucrative market segment, driving overall growth in the biopharmaceuticals industry.

• Technological Advancements in Biotechnology

Innovations in biotechnology, particularly advancements like CRISPR gene editing and cutting-edge manufacturing techniques, are significantly reshaping the biopharmaceutical landscape. CRISPR technology allows for precise modifications in the genetic material of organisms, facilitating the development of targeted therapies and novel drug candidates for various diseases, including genetic disorders and cancers. In addition, improvements in manufacturing processes, such as continuous bioprocessing and single-use technologies, enhance the efficiency and scalability of biopharmaceutical production. These innovations reduce production costs and shorten development timelines, allowing companies to bring therapies to market more quickly. As the demand for innovative and effective treatments grows, leveraging these biotechnological advancements presents a valuable opportunity for market players to enhance their product offerings and strengthen their competitive positions within the biopharmaceutical industry.

Restraints/Challenges

• Shortage of Skilled Professionals

The biopharmaceutical industry is currently facing a significant challenge due to a shortage of skilled professionals in biotechnology and related fields. This lack of expertise hampers innovation and development efforts, as organizations struggle to recruit and retain qualified scientists, researchers, and technicians necessary for advancing biopharmaceutical research and production. The complex nature of biopharmaceutical development requires specialized knowledge in areas such as molecular biology, biochemistry, and regulatory affairs. As a result, companies may experience delays in bringing new therapies to market, reducing their competitive edge in a rapidly evolving industry. Furthermore, the shortage of skilled workers can lead to increased operational costs and limited capacity for research and development initiatives.

• High Production Costs

The manufacturing processes involved in biopharmaceuticals are inherently complex and costly, necessitating specialized facilities, advanced technology, and stringent quality controls. These high production costs can pose significant challenges for biopharmaceutical companies, as they may struggle to set competitive prices for their products. As a result, the affordability and accessibility of essential medications can be compromised, limiting patient access to innovative therapies. Smaller companies, in particular, may find it difficult to bear these expenses, which can inhibit their ability to bring new products to market. In addition, the economic burden of high production costs can lead to reduced investment in research and development, ultimately stifling innovation within the industry.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Biopharmaceuticals Market Scope

The market is segmented on the basis of product type, service, raw material type, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Monoclonal Antibodies
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Recombinant Hormones
• Vaccines
• Synthetic Immunomodulatory Agents
• Other

Service

• Laboratory Testing
• Custom Testing / Customer Proprietary Testing
• Compendial Testing
• Multi-Compendial Laboratory Testing

Raw Material Type

• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Compendial Methods (USP / EP / JP) Based Vendor Qualification Program Support

Application

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

Biopharmaceuticals Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, service, raw material type, and application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global biopharmaceuticals market, driven by a robust network of healthcare facilities and cutting-edge treatment options. This region excels in delivering therapies that target the root causes of complex diseases, resulting in better therapeutic outcomes. Consequently, the enhanced quality of patient care in North America reinforces its dominant position in the biopharmaceutical sector.

Asia-Pacific is projected to experience substantial growth from 2024 to 2031, fueled by heightened government initiatives aimed at raising awareness and promoting health advancements. The region is also benefiting from rapid technological innovations that enhance healthcare delivery and accessibility. In addition, the increasing demand for high-quality healthcare services among the population further contributes to the region's robust market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Biopharmaceuticals Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Biopharmaceuticals Market Leaders Operating in the Market Are:

• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Sanofi (France)
• Abbott (U.S.)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• BIOMÉRIEUX (France)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Novo Nordisk A/S (Denmark)
• Merck & Co., Inc. (U.S.)
• GSK Plc (U.K.)
• Biogen (U.S.)
• Bayer AG (Germany)
• Pfizer Inc. (U.S.)

Latest Developments in Biopharmaceuticals Market

• In March 2023, F. Hoffmann-La Roche Ltd partnered with Eli Lilly and Company to advance the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). This cutting-edge blood test is designed to enhance the early diagnosis of Alzheimer’s disease, offering potential improvements in patient outcomes. The collaboration highlights both companies' commitment to innovation in Alzheimer's detection and treatment
• In August 2022, AstraZeneca's Evusheld, a long-acting antibody combination comprising tixagevimab and cilgavimab (previously known as AZD7442), has been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW). This therapy is indicated for both the prevention and treatment of symptomatic disease resulting from SARS-CoV-2 infection. The approval highlights AstraZeneca's ongoing efforts to provide effective therapeutic options in the fight against COVID-19
• In February 2022, Johnson & Johnson Services, Inc. received approval from the U.S. FDA for CARVYKTI, a groundbreaking CAR-T therapy specifically designed for the treatment of refractory multiple myeloma in adults. This innovative therapy offers new hope for patients who have not responded to prior treatments, showcasing advancements in personalized medicine for cancer care. The approval underscores Johnson & Johnson's commitment to developing effective solutions for complex hematological conditions
• In February 2021, Bristol Myers Squibb entered into a definitive agreement with The Rockefeller University, acquiring a worldwide exclusive license to develop, manufacture, and market a novel monoclonal antibody duo for COVID-19 therapy and prevention. This innovative treatment leverages two monoclonal antibodies designed to target and neutralize the SARS-CoV-2 virus by blocking its spike protein. The collaboration underscores Bristol Myers Squibb's commitment to advancing therapeutic solutions against COVID-19 through cutting-edge antibody technology
• 2021年2月、アッヴィはカリブーバイオサイエンス社と提携し、キメラ抗原受容体（CAR）T細胞療法の研究開発に重点を置いたライセンス契約を締結しました。この提携は、カリブーの革新的な遺伝子編集技術を活用して、がん治療におけるCAR T細胞療法の有効性と安全性を高めることを目的としています。この契約は、免疫腫瘍学の分野における画期的な治療法の推進に対する両社の取り組みを反映しています。

SKU-23925